Ayala Pharmaceuticals (NASDAQ:ADXS) & Nabriva Therapeutics (NASDAQ:NBRV) Head-To-Head Comparison

Insider and Institutional Ownership

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ayala Pharmaceuticals and Nabriva Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24 million	11.05	-$48.07 million	($5.02)	-0.12
Nabriva Therapeutics	$35.59 million	0.00	-$57.19 million	($19.20)	N/A

Ayala Pharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares Ayala Pharmaceuticals and Nabriva Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Summary

Ayala Pharmaceuticals beats Nabriva Therapeutics on 7 of the 10 factors compared between the two stocks.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.